Peanut allergy is an increasing public health concern in the United States. Children with peanut allergy may remain allergic for life, unlike children with more often outgrown allergies to milk or egg. Dr. Wesley Burks, professor and chief of the division of pediatric allergy and immunology at Duke University Medical Center, describes recent success with peanut immunotherapy in a few groups of children. Do these studies provide hope for all patients with peanut allergy, including adults? Dr. Lee Freedman hosts.
Promising Peanut Immunotherapy Studies
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Peanut allergy is an increasing public health concern in the United States. Children with peanut allergy may remain allergic for life, unlike children with more often outgrown allergies to milk or egg. Dr. Wesley Burks, professor and chief of the division of pediatric allergy and immunology at Duke University Medical Center, describes recent success with peanut immunotherapy in a few groups of children. Do these studies provide hope for all patients with peanut allergy, including adults? Dr. Lee Freedman hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
0.25 credits
<p>Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">M3: Managing the Cardiometabolic Risk in MASH</span><span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'> </span></p>
MinuteCE®
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
1.00 credits
<p><span data-contrast="none" xml:lang="EN-US">Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli</span> </p>
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 credits
<p>Maximizing Adherence and Persistence via Patient Engagement</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?